Trial ID or NCT#

NCT01397578

Status

RECRUITING

Purpose

This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of MABT5102A on brain amyloid burden (as assessed by amyloid PET imaging) and other biomarkers in patients with mild to moderate Alzheimer's disease.

Official Title

A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Eligibility Criteria

Ages Eligible for Study: 50 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Contact us to find out if this trial is right for you.

CONTACT

Christina Wyss-Coray
(650) 721-2409